ストックスクリーナーアプリを入手
3.82
3.54%
-0.14
前日終値:
$3.96
開ける：
$3.96
24時間の取引高:
296.38K
Relative Volume:
0.35
時価総額：
$292.09M
収益：
$114.70K
当期純損益:
$-26.49M
株価収益率:
-1.5488
EPS:
-2.4665
ネットキャッシュフロー:
$-53.17M
1週間 パフォーマンス:
-2.55%
1か月 パフォーマンス:
+15.41%
6か月 パフォーマンス:
+3.80%
1年 パフォーマンス:
+52.79%
1日の値動き範囲:
$3.72
$3.96
1週間の範囲:
$3.54
$4.07
52週間の値動き範囲:
$1.85
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Compare SABS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.82 | 292.09M | 114.70K | -26.49M | -53.17M | -2.4665 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-02 | 開始されました | Rodman & Renshaw | Buy |
| 2025-12-19 | 開始されました | Guggenheim | Buy |
| 2025-09-17 | 開始されました | Leerink Partners | Outperform |
| 2025-05-14 | 再開されました | H.C. Wainwright | Buy |
| 2024-10-09 | 開始されました | Craig Hallum | Buy |
| 2024-08-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Sab Biotherapeutics Inc (SABS) 最新ニュース
SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial - TipRanks
Breakthrough T1D Awards Grant for SAB-142 PRISE-hATG Study to Advance Type 1 Diabetes Therapies Beyond 100 Days Post-Diagnosis – Minichart - Minichart
Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes - TradingView
Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial - Stock Titan
Breakthrough T1D backs SAB-142 study beyond the first 100 days - Stock Titan
Wall Street Analysts Lift SAB Biotherapeutics Stock Over Diabetes Drug - HarianBasis.co
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Yahoo Finance
SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings - TradingView
Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
SABSW Plunges to Penny Level as Biotech Warrant Faces Continued Selling PressureSupport Level Bounce - dars.gov.et
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Value Benchmark Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Value Benchmark - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell Microcap Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Value Benchmark - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Small Cap Completeness Index - marketscreener.com
Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView
Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView
Form 4 SAB Biotherapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
SAB Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:SABS) - TradingView
SABS Forecast — Price Target — Prediction for 2027 - TradingView
SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jun 2026 $SABS - MarketBeat
Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 By Investing.com - Investing.com South Africa
Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target - marketscreener.com
Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 - Investing.com
SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SABS Q1 2026 Earnings: EPS Misses Estimates as Operational Costs ClimbEarnings Growth Analysis - dars.gov.et
Citi Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
SAB Biotherapeutics (SABS) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SAB Biotherapeutics Inc (SABS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SAB Biotherapeutics shareholders elect directors and approve auditor at annual meeting - Investing.com UK
SAB Biotherapeutics, Inc. 8-K SEC Filing Details for June 18, 2026: Company Information & Nasdaq Listing - Minichart
SAB Biotherapeutics Shareholders Back Board and Auditor - TipRanks
SAB Biotherapeutics (NASDAQ: SABS) investors back board slate and auditor - Stock Titan
SAB Biotherapeutics Inc (SABS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SAB Biotherapeutics Inc (SABS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SAB Biotherapeutics Inc (SABS) Institutional Confidence - TradingKey
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey
SAB Biotherapeutics Inc (SABSW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SAB Biotherapeutics Inc (SABSW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SAB Biotherapeutics Inc (SABSW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SAB Biotherapeutics Inc (SABSW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SAB Biotherapeutics Inc (SABSW) Valuation: PE, PB & Fair Value Analysis - TradingKey
SAB Biotherapeutics Inc (SABSW) Institutional Confidence - TradingKey
SABS Maintained by Chardan Capital -- Price Target Raised to $16 - GuruFocus
Sab Biotherapeutics Inc (SABS) 財務データ
収益
当期純利益
現金流量
EPS
Sab Biotherapeutics Inc (SABS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
2.64%
大文字化:
|
ボリューム (24 時間):